cabozantinib
FDA Approves Cabometyx for pNET and epNET
The FDA granted approval for cabozantinib (Cabometyx, Exelixis) for adult and pediatric patients 12 years of age ...
MARCH 26, 2025
Study Reports Long-Term Data for Nivolumab Plus Cabozantinib in Advanced RCC
Nivolumab plus cabozantinib outperforms sunitinib for first-line treatment of advanced clear cell renal cell ...
MARCH 22, 2023
Cabozantinib Beneficial in Radioactive Iodine-Refractory DTC
Cabozantinib significantly improved progression-free survival in certain patients with radioactive ...
NOVEMBER 3, 2021
Cabometyx Approved for Metastatic Differentiated Thyroid Cancer
The FDA approved cabozantinib (Cabometyx, Exelixis) for adult and pediatric patients 12 years of age and older with ...
SEPTEMBER 30, 2021
FDA Grants Cabometyx New Indication for HCC
The FDA granted a new indication to cabozantinib (Cabometyx, Exelixis) for patients with hepatocellular carcinoma ...
JANUARY 16, 2019
Cabometyx Approved for First-Line Treatment of Advanced RCC
The FDA has granted regular approval to cabozantinib (Cabometyx, Exelixis) for the treatment of patients with ...
DECEMBER 20, 2017
Cabozantinib Improves PFS in Advanced RCC
Cabozantinib can improve PFS in patients with previously untreated advanced or metastatic RCC, according to updated ...
SEPTEMBER 21, 2017
Is Cabozantinib a Standard of Care for Advanced RCC?
A final report from the Phase III METEOR trial makes a solid case that cabozantinib is a new standard of care in ...
MAY 9, 2017
Cabozantinib Beats Sunitinib In Metastatic RCC Study
In first-line treatment of poor- or intermediate-risk mRCC, cabozantinib results in a substantially longer ...
NOVEMBER 8, 2016
METEOR Trial: Cabozantinib Shows Benefit Over Everolimus in RCC
Chicago—Cabozantinib offers a new treatment standard for patients with advanced renal cell carcinoma (RCC) ...
SEPTEMBER 19, 2016
Drugs Strike Out in Ovarian Cancer
Two therapies that once appeared promising for recurrent ovarian cancer—cabozantinib and an oncolytic ...
JULY 5, 2016
Optimizing Second-Line Rx For Renal Cell Carcinoma
San Francisco—Results from two randomized, Phase III clinical trials presented at the American Society of ...
FEBRUARY 25, 2016
